ライフサイエンスコーパス: progression-free survival rate

1 t Milan criteria provides a high local tumor progression-free survival rate.

2 response rate and the 20-week immune-related progression-free survival rate.

3 mide backbone and has promising response and progression-free survival rates.

4 Actual progression-free survival rates 10 years after radical p

5 rate, 71% [5 of 7 patients]; immune-related progression-free survival rate, 67% [4 of 6 patients]).

6 The absolute difference in the 3-year progression-free survival rate (ABVD minus AVD) was 1.6

7 The primary end point was the progression-free survival rate after 6 months (PFS-6).

8 e improved overall radiographic response and progression-free survival rates, although the impact of

9 a median follow-up of 41 months, the 3-year progression-free survival rate and overall survival rate

10 time of 42 months, the estimated overall and progression-free survival rates are 68% and 42%, respect

11 , does one have a well-documented historical progression-free survival rate at 1 year for comparison

12 Progression-free survival rate at 2 years was 52.4%.

13 The progression-free survival rate at 36 months was 58%.

14 The progression-free survival rates at 12 months were 43.6%,

15 Estimated progression-free survival rates at 24 months were 51% an

16 Progression-free survival rates at 6 months were 41.8% a

17 Cumulative survival and progression-free survival rates at more than 4.5 years w

18 ary outcome was the difference in the 3-year progression-free survival rate between randomized groups

19 The 5-year progression-free survival rate for patients with depth o

20 The 2- and 5-year progression-free survival rates for all 49 patients trea

21 f 33 months (range,17-94 months), the 3-year progression-free survival rates for patients with chemor

22 zard ratio [HR] 1.05; 95% CI 0.95-1.17), and progression free survival rates (HR 1.01; 95% CI, 0.92-1

23 more percentage points from the assumed 95% progression-free survival rate in the radiotherapy group

24 ear overall survival rate is 76%, the 3-year progression-free survival rate is 56%, and the 3-year lo

25 The overall survival and progression-free survival rates observed in this trial a

26 e survival time was 13 months, with a 2-year progression-free survival rate of 26.4%.

27 all objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overal

28 ulting in a 63% durable CR rate and a 2-year progression-free survival rate of 65% (95% CI, 51% to 79

29 signed to exclude a difference in the 3-year progression-free survival rate of 7 or more percentage p

30 l (24 from Hodgkin's lymphoma), for a 3-year progression-free survival rate of 82.6% and an overall s

31 had disease progression or died, with 2-year progression-free survival rates of 69 and 55%, respectiv

32 , with estimated 3-year overall survival and progression-free survival rates of 73% (95% confidence i

33 rates of 87%, 64%, 53%, and 22%, and 5-year progression-free survival rates of 83%, 55%, 33%, and 12

34 Progression-free survival rates of patients who underwen

35 Secondary outcomes were progression-free survival; rates of grade 3 or 4 adverse

36 (22% v 11%; P = .034), but decreased 3-year progression-free survival rates (P < .0001) and 3-year o

37 nsplantation for both overall (P = .001) and progression-free survival rates (P < .001).

38 included objective response rate and 24-week progression-free survival rate (per Response Evaluation

39 response rate, complete remission (CR) rate, progression-free survival rate (PFS), and OS.

40 ts compared with historical series; however, progression-free survival rates remain disappointing, ra

41 abine-docetaxel was associated with a 2-year progression-free survival rate that appears superior to

42 The 6-month progression-free survival rate was 10% (95% CI, 2% to 26

43 nths (95% CI, 1.8 to 2.1 months) and 4-month progression-free survival rate was 13% +/- 5%.

44 The 5-year progression-free survival rate was 21% +/- 8%.

45 The 6-month progression-free survival rate was 32% (95% CI, 14% to 5

46 t a median follow-up of 370 days, the 1-year progression-free survival rate was 58.2% (95% CI, 33.1%-

47 After 18 months, the progression-free survival rate was 63.0% (95% confidence

48 The overall progression-free survival rate was 67% (95%, CI: 61%-73%

49 findings on a third PET-CT scan; the 3-year progression-free survival rate was 67.5% and the overall

50 The progression-free survival rate was 69% at 24 weeks and 4

51 The 6-month progression-free survival rate was 7.7% for the glioblas

52 median follow-up of 23 months, the 36-month progression-free survival rate was 72%.

53 In the U.S. trial, at 1 year, the progression-free survival rate was 73% and the overall s

54 At 26 months, the estimated progression-free survival rate was 75% and the rate of o

55 1 to 21.2 months), and the estimated 1-year progression-free survival rate was 8%.

56 ad a major response), the estimated 18 month progression-free survival rate was 86% (95% CI 66-94), a

57 6.6 years (range, 0.1-12 years), the 6-year progression-free survival rate was 88% (95% confidence i

58 The 3-year progression-free survival rate was 94.6% (95% confidence

59 e of 25 months, the estimated 3-year current progression-free survival rate was 95%.

60 e was 196 months (16.3 years) and the median progression-free survival rate was 98 months (8.2 years)

61 The progression-free survival rate was better after a comple

62 Progression-free survival rate was the same after lobect

63 d objective response rate and immune-related progression-free survival rate were 40% (4 of 10 patient

64 The median overall and progression-free survival rates were 28 and 14 months, r

65 Twelve-month progression-free survival rates were 35% (95% CI, 31%-39

66 ab-plus-irinotecan groups, estimated 6-month progression-free survival rates were 42.6% and 50.3%, re

67 lts The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to

68 Three- and 6-month progression-free survival rates were 47% and 33% for cho

69 3%, 47%, 47%, and 43%, respectively; 24-week progression-free survival rates were 51%, 71%, 38%, and

70 The estimated 3-year overall and progression-free survival rates were 59% and 51%, respec

71 The 1-, 2-, and 3- year progression-free survival rates were 70%, 57%, and 50%,

72 months, respectively; the 1-year overall and progression-free survival rates were 76% and 59%, respec

73 Their 3-year progression-free survival rates were 78%, 33%, and 0%, r

74 42 months), the 11-year overall survival and progression-free survival rates were 78%, and 72%, respe

75 5-year progression-free survival rates were 81% (95% CI 71-87)

76 The 1-year overall and progression-free survival rates were 82% and 73%, respec

77 The overall 5- and 7-year progression-free survival rates were 82% and 80%, respec

78 s (range, 19-94), the estimated survival and progression-free survival rates were 85% and 83%, respec

79 With a median follow-up of 23 months, 2-year progression-free survival rates were 86% for interim PET

80 The estimated 10-year progression-free survival rates were 9.5% and 9.2% for t

81 (range, 6-50 months), the 2-year overall and progression-free survival rates were 90% and 75%.

82 r-month actuarial overall and local-regional progression-free survival rates were both 50%.

83 The overall progression-free survival rates were similar between the

84 The estimated 6-month progression-free-survival rates were 47.3% for pembroliz

85 The primary end point was 6-mo progression-free survival rate, which was 74% (95% CI: 5